Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as eating ...

"There will be a cure for Parkinson's one day." Follow BBC Hereford & Worcester on BBC Sounds, Facebook, X and Instagram.

Inhibikase Therapeutics, Inc. (IKT), a biopharmaceutical company with a market capitalization of $189.48 million, has announced the halting of further development of its Parkinson's disease drug, ...

The findings revealed a potential link between the use of these drugs and an increased risk of Parkinson’s disease. The risk ...

Researchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics ...

Jan. 3, 2025 — Researchers uncovered new findings about involuntary muscle movements that come with long-term administration of Parkinson's drug ... 'Dancing the Blues Away' Seen in Brain ...

The FDA approved a monthly maintenance dosing of intravenous lecanemab (Leqembi) for early Alzheimer's disease, said ...

"Now that we know how Aplp1 and Lag3 interact, we have a new way of understanding how alpha-synuclein contributes to the ...

In a large cohort of patients with autoimmune diseases, treatment with biologic disease-modifying antirheumatic drugs was ...